47 results about "EXPECTORANT AGENTS" patented technology

A pharmaceutical dosage form comprising a first drug and a second drug, both of which are selected from decongestants, antitussives, expectorants, analgesics and antihistamines. The dosage form provides a plasma concentration within a therapeutic range of the second drug over a period which is coextensive with at least about 70% of a period over which the dosage form provides a plasma concentration within a therapeutic range of the first drug. This Abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.

The present invention relates to a sustained release oral pharmaceutical tablet formulation containing an expectorant and a decongestant.

This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity, throat or nose of warm-blooded animals including humans. More particularly, the invention pertains to a composition and method for spraying essential oils to the oral cavity, throat or nasal mucosa as cyclodextrin inclusion complexes. The spray composition includes a cyclodextrin in an amount of from about 0.1% w / v to about 20% w / v; at least one essential oil in an amount of from about 0.001% w / v to about 5.0% w / v; an effective amount of an antimicrobial preservative composition; and water. The composition may further comprise an alcohol co-solvent, a thickening agent, a sweetener, an antitussive, an anticholinergic, a decongestant, an antihistamine, an astringent, an anti-inflammatory steroid composition, a vitamin, a respiratory stimulant, a mucolytic agent, a bronchodilator, a beta-antagonist, an antidiarrheal agent, or combinations thereof.

This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.

Provided is a method of liquefying mucus from mucosal surfaces by administering compounds containing a phosphine group.

A monoclonal antibody-based Dot-ELISA assay for the rapid detection of animal viruses such as avian influenza virus. The assay includes applying a specimen suspected of containing an animal virus on a porous membrane and treating the specimen with a solution of citric acid or lactic acid and a solution containing a mucolytic agent and a detergent. The treated specimen is then contacted with a primary monoclonal antibody for detecting the virus. If present, the primary moncolonal antibody bind with an antigen of the animal virus specimen. The specimen is contacted with an anti-monoclonal antibody conjugate (secondary antibody) and incubated to facilitate binding of the antigen-bound monoclonal antibody to the conjugate. The bound conjugate and antigen-bound monoclonal antibody is contacted with a coloring reagent to allow visual detection of the presence of the animal virus in the specimen.

The present invention relates to a method for inhibiting bacterial colonisation of mucous epithelium in a biological system. The method includes the step of administering to the biological system an effective amount of a mucolytic agent and one or more of colostrum, hyperimmune milk, or a component of colostrum and / or hyperimmune milk that is capable of inhibiting bacterial colonisation in combination with the mucolytic agent.

A nasal passage cleaning composition according to the invention comprises water and salt as a base, and contains a mucolytic agent such as alum and / or zinc sulphate to shrink the mucosa and allow sinus passage drainage, decreasing pressure in the infected sinus an alleviates sinus headache and face ache. A preferred mucolytic agent is n-acetyl-L-cystine, which is used to dissolve or soften mucus in the nasal passages, though methyl salicylate may also be used to disintegrate crusted mucus, acting also as a topical anti-inflammatory agent and as a pain relieving agent to reduce pain and discomfort.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The invention relates to exfoliated cell preservation solution and a preparation method thereof. The preservation solution comprises the following components in percentage by weight: 0.6 percent of sodium chloride, 0.06 percent of potassium chloride, 2 percent of glucose, 20 percent of ethanol, 3 percent of 1-3 propylene glycol, 2 percent of glycerin, 0.15 percent of glycine, 0.1 percent of mucolytic agent, 0.2 percent of cell protective agent, 0.1 percent of heparin sodium and 0.05N of sodium benzoate-benzoic acid buffer solution. A pH value is adjusted by 1 percent sodium hydroxide or hydrochloric acid solution to ensure that the pH of the preservation solution is 5.8. By the exfoliated cell preservation solution, cells can be well preserved and the preservation time is more than 10 days; cell nucleuses are clear, and cytoplasm is stretched; red blood cells and mucus are effectively removed; the cells are dispersed and flatly laid and an acid phosphatase (ACP) enzyme is well preserved simultaneously; and the exfoliated cell preservation solution is suitable for ACP enzyme staining.

Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.

The invention provides a cell preservation solution and application thereof. The cell preservation solution is prepared from the following components in parts by weight: 60 to 1000 parts of pH buffer, 10 to 150 parts of osmotic pressure maintenance agent, 4 to 55 parts of anticoagulant, 1 to 30 parts of mucolytic agent, 800 to 5000 parts of fixing agent, 1 to 150 parts of component A, 10 to 30 parts of component B and 10000 to 20000 parts of water, wherein the component A is prepared from sodium azide and lauryl sodium sulfate according to a weight ratio of (1 to 10) to (2 to 110); the component B is carbon disulfide. The cell preservation solution of the invention has a better impurity treatment effect, and reduces the interference factors in cell samples; at the same time, target cells therein can retain the characteristics of structural morphology for a long time, thereby facilitating the medical detection and analysis of the target cells, and the cost is low.

Methods for isolating and purifying fetal trophoblasts from a mucus sample obtained from the uterine cavity of a pregnant female. The mucus sample is transported from a clinical collection facility to a laboratory in a transportation medium so the cells remain viable. The mucus sample is then subjected to precise processing steps, including treatment with mucolytic agents or mucinases, sugar hydrolysis enzymes, nucleases, and proteases to provide fetal cells, the outer surfaces of which are so essentially completely devoid of attached mucosal biological material that they are then isolated in greater numbers than previously had been possible. The isolated cells are in appropriate condition to immediately be effectively subjected to FISH or to other molecular diagnostics.

Methods of treating pulmonary sarcoidosis are described herein. Patients in need of treatment for pulmonary sarcoidosis are administered a therapeutically effective amount of a mucolytic agent such as DNase I. In some embodiments, the DNase I is a recombinant human DNase I such as dornase alfa.

Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. Compositions as aqueous solutions can include water as a carrier. Preferred embodiments include water, guanidine thiocyanate, Tris, EDTA, SLS, SDA 3C, HCl, and N-acetyl-L-cysteine. Some embodiments include a colored dye as a visual indicator. Methods of manufacturing include combining the components into a mixture, such as an aqueous solution. Methods of use include providing a biological sample that includes nucleic acid and contacting the biological sample with the composition. Kits include the composition disposed in a portion of a biological sample collection apparatus.

A monoclonal antibody-based Dot-ELISA assay for the rapid detection of animal viruses such as avian influenza virus. The assay includes applying a specimen suspected of containing an animal virus on a porous membrane and treating the specimen with a solution of citric acid or lactic acid and a solution containing a mucolytic agent and a detergent. The treated specimen is then contacted with a primary monoclonal antibody for detecting the virus. If present, the primary moncolonal antibody bind with an antigen of the animal virus specimen. The specimen is contacted with an anti-monoclonal antibody conjugate (secondary antibody) and incubated to facilitate binding of the antigen-bound monoclonal antibody to the conjugate. The bound conjugate and antigen-bound monoclonal antibody is contacted with a coloring reagent to allow visual detection of the presence of the animal virus in the specimen.

A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.

Devices and methods incorporate mucolytic agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters one or more lysis agents and / or mucolytic agents. The mucolytic agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the mucolytic agent is localized between the sample application zone and the conjugate zone. In embodiments with a sample compressor, one or more mucolytic agents may be pre-loaded and dried on the sample compressor, the sample collector, in various locations on the test strip, or in the running buffer.

According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided.

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Methods for isolating and purifying fetal trophoblasts from a mucus sample obtained from the uterine cavity of a pregnant female. The mucus sample is transported from a clinical collection facility to a laboratory in a transportation medium so the cells remain viable. The mucus sample is then subjected to precise processing steps, including treatment with mucolytic agents or mucinases, sugar hydrolysis enzymes, nucleases, and proteases to provide fetal cells, the outer surfaces of which are so essentially completely devoid of attached mucosal biological material that they are then isolated in greater numbers than previously had been possible. The isolated cells are in appropriate condition to immediately be effectively subjected to FISH or to other molecular diagnostics.

A subglottic suctioning system with a tracheal tube (10) having a ventilation lumen, a cuff inflation lumen (14), and a suction lumen (16) are disclosed which may help reduce the incidence of ventilator associated (or acquired) pneumonia. The suction lumen communicates with the space in the trachea above the cuff (22) where secretions accumulate. The suction lumen has a valve (36) on the proximal end for connection to a source of vacuum. The valve is adapted to interrupt the supply of vacuum to the suction lumen to allow for the introduction of a rinsing fluid in its place and to automatically re-establish the connection to the source of vacuum upon completion of rinsing. The rinsing fluid aids in maintaining an open suction lumen and may include medicaments and mucolytic agents to enhance or promote healing or to alter the properties of the mucus to make removal easier. The user may easily and repeatedly alternate suction and rinsing fluid through the suction lumen, i.e., the user may 'pulse' the line to loosen, break up and remove secretions and deposits that may partially or completely block or clog the suction lumen.

An orally administered composition for relieving or eliminating snoring is described. The composition generally has four mechanisms of action for combating snoring. The composition includes a tissue-firming or astringent agent to firm up throat tissue. The composition also includes a soothing agent to soothe irritated or inflamed tissues. Also included in the composition is a lubricant to moisten dry or dehydrated tissues, and a mucous-thinning or expectorant agent to help remove any obstructive matter near the throat tissues.

An orally administered composition for relieving or eliminating snoring is described. The composition generally has four mechanisms of action for combating snoring. The composition includes a tissue-firming or astringent agent to firm up throat tissue. The composition also includes a soothing agent to soothe irritated or inflamed tissues. Also included in the composition is a lubricant to moisten dry or dehydrated tissues, and a mucous-thinning or expectorant agent to help remove any obstructive matter near the throat tissues.

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.

The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates / debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin / conjunctival keratinization, corneal neovascularization / pannus, subconjunctival fibrosis, and herpetic eye disease. The present invention also provides a method for diagnosing or monitoring an ocular surface disease.